Galderma Q3超预期并上调2026全年销售增速指引，Nemluvio强劲放量

Introduction & Market Context
Galderma Group AG (SIX:GALD) presented its third-quarter 2026 trading update on October 22, showcasing record nine-month net sales of $4.765 billion and raising its full-year revenue growth guidance, according to the company’s investor presentation. The Swiss dermatology specialist’s shares surged 7.32% to $187 following the announcement, approaching the 52-week high of $188.25, as investors responded positively to both the revenue beat and improved outlook.
The company raised its 2026 net sales growth guidance to 22.5-23.5% at constant currency, up from the previous 19-21% range, while maintaining its Core EBITDA margin target of approximately 26%. The updated guidance reflects sustained momentum across all three business segments and exceptional performance from Nemluvio, the company’s blockbuster therapy for prurigo nodularis and atopic dermatitis.
Financial Performance Highlights
As shown in the following summary of key financial metrics, Galderma delivered broad-based growth across its portfolio during the first nine months of 2026:
The company’s Q3 YTD 2026 net sales reached $4.765 billion, representing 25.1% growth at constant currency compared to the prior-year period. This performance was driven by what management described as "execution of a proven, growth-driven integrated dermatology strategy, focused on the core portfolio, complemented by innovation & further geographic penetration."
The regional breakdown reveals particularly strong performance in the United States, as illustrated in the following chart:
U.S. sales climbed to $2.130 billion, up 34.7% at constant currency, while international markets contributed $2.636 billion, growing 18.0% at constant currency. The substantial U.S. outperformance reflects robust demand for Nemluvio and continued market share gains across the portfolio.
Segment Analysis
Therapeutic Dermatology: Nemluvio Drives Exceptional Growth
The therapeutic dermatology segment emerged as the standout performer, with net sales reaching $1.347 billion in the first nine months, representing 64.4% constant currency growth. The following chart highlights Nemluvio’s substantial contribution to this segment:
Nemluvio (nemolizumab-ilto) generated $735 million in nine-month sales, with third-quarter sales exceeding $300 million—a 22% sequential increase from Q2. The therapy is approaching market leadership in prurigo nodularis and gaining traction in atopic dermatitis, as detailed in the company’s market share data:
According to rolling six-week prescription data as of October 9, 2026, Nemluvio captured approximately 45% of paid new patient starts and 37% of total prescriptions in prurigo nodularis. In atopic dermatitis, the therapy achieved roughly 9% of new patient starts and 5% of total prescriptions, with the majority of patients being biologic-naïve.
New three-year extension study data demonstrated sustained improvements in skin clearance, with EASI-75 response rates reaching 90.6% for previously experienced patients and 88.2% for treatment-naïve patients by week 152.
Injectable Aesthetics: Portfolio Expansion Continues
The injectable aesthetics segment generated $2.174 billion in nine-month sales, up 13.2% at constant currency, as shown in the following breakdown:
Neuromodulators led segment growth at 16.9% constant currency, reaching $1.259 billion, while fillers and biostimulators contributed $914 million with 8.5% growth. The company’s expansion strategy focuses on geographic penetration and product innovation:
Key developments included the expansion of Sculptra into Southeast Asian markets (India, Indonesia, Vietnam), the launch of Restylane GAIN in Europe with new injection techniques for chin augmentation, and positive Phase III data for Restylane VOLYME to support expansion in China. The company is also preparing for a U.S. resubmission of relfydess in Q1 2027, pending additional FDA feedback.
Dermatological Skincare: Core Brands Deliver Steady Growth
The dermatological skincare segment posted $1.244 billion in nine-month sales, up 16.2% at constant currency:
Cetaphil and Alastin drove the segment’s performance through focused execution. As detailed in the company’s brand strategy presentation:
Cetaphil’s growth strategy centers on three fundamentals: strong core equity as a sensitive skin brand recommended by dermatologists, focus on core products (which drove over 60% of global growth), and locally relevant activation campaigns. Alastin maintained its position as the #1 preferred physician-dispensed brand overall and for procedure pairing, with brand familiarity among healthcare professionals increasing 25% year-over-year.
Strategic Initiatives
Galderma’s integrated dermatology strategy continues to drive market share gains across all three product categories, as illustrated in the company’s strategic framework:
The company’s approach combines the industry’s broadest portfolio with leading science and innovation, global scale with omni-channel execution, and market-leading education and services. The strategy has enabled Galderma to reach over 100 million consumers through top campaigns, achieve over 25% e-commerce sales growth, and engage more than 290,000 healthcare participants annually through over 10,000 educational events.
ZO Skin Health Acquisition
A centerpiece of Galderma’s growth strategy is the pending acquisition of ZO Skin Health, announced October 13, 2026, as detailed in the following overview:
The $1.5 billion all-cash transaction will add a leading science-based, physician-endorsed skincare brand with approximately $330 million in annual net sales (last twelve months as of June 2026). The acquisition extends Galderma’s position in the fast-growing physician-dispensed skincare category, complementing Alastin’s peri-procedure focus with ZO’s broader product portfolio.
However, management tempered expectations for immediate growth, noting that integration will require investment and the acquisition is expected to be slightly dilutive to Core EBITDA margin in 2027 before achieving margins comparable to the group average from 2028 onwards. Integration and one-time costs are estimated at $50-60 million over the first two years.
Outlook & Guidance
The company’s updated full-year 2026 guidance reflects confidence in sustained momentum across the portfolio:
Galderma raised net sales growth guidance to 22.5-23.5% at constant currency while confirming the Core EBITDA margin target of approximately 26%. The guidance excludes potential effects from the ZO Skin Health acquisition and assumes a 15% U.S. tariff on certain imports.
Management indicated that fourth-quarter growth will face tougher year-over-year comparisons due to Nemluvio’s larger base in late 2025. The company also expects lower channel inventory levels in Brazil as tax reform approaches in 2027.
CEO Flemming Ørnskov stated the company is "driving growth across the core portfolio, complemented by innovation and further increasing penetration in fast-growing markets." He emphasized that "Nemluvio is the first therapy to demonstrate freedom of itch," highlighting the product’s differentiation in a competitive market.
CFO Luigi La Corte noted that revenue growth of 25.1% at constant currency was "predominantly driven by volume," with pricing also positive excluding expected gross-to-net erosion on Nemluvio.
Capital Allocation and Financial Discipline
The company outlined its unchanged capital allocation priorities:
Galderma will continue prioritizing organic growth through investments in commercial footprint, R&D, and capital expenditures, while pursuing selective business development and licensing opportunities across its three product categories. The company maintains a progressive ordinary dividend policy targeting up to 20% of prior-year reported net income and will use share repurchases opportunistically to enhance earnings per share returns.
Management emphasized its commitment to maintaining a strong balance sheet with a solid investment-grade credit rating, even as it funds the ZO Skin Health acquisition through existing cash reserves and bank financing.
The combination of raised guidance, strategic M&A, and sustained momentum across all business segments positions Galderma for continued outperformance in the dermatology market, though integration challenges and competitive pressures remain key areas for investor focus heading into 2027.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.